CymaBay Therapeutics, Inc.
CBAYDelisted Mar 22, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001042074
CymaBay Therapeutics, Inc. was delisted on Mar 22, 2024; its insiders filed their last Form 4 on Mar 22, 2024; 200 institutions reported holding it in 13F filings for Q4 2023, worth $2.71B in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:13 PM ET
Revenue flow, FY2023
Where the revenue went in FY2023, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2023: $105.4M (339.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 16, 2023 | – | – | Jan 29, 2020 |
| Revenue | $31.1M | – | – | – | – |
| Operating expenses | $132.8M | $93.1M | $87.6M | $52.6M | $108.2M |
| Research and development | $80.8M | $68.0M | $64.5M | $35.9M | $83.8M |
| Selling, general and administrative | $52.0M | $25.1M | $23.0M | $17.4M | $19.2M |
| Operating income | -$101.7M | -$93.1M | -$87.6M | -$52.6M | -$108.2M |
| Interest expense | $18.9M | $14.9M | $2.58M | – | – |
| Income tax | $0 | $0 | $0 | $0 | – |
| Net income | -$105.4M | -$106.0M | -$90.0M | -$51.0M | -$102.8M |
| EPS, basic | $-0.99 | $-1.21 | $-1.27 | $-0.74 | $-1.53 |
| EPS, diluted | $-0.99 | $-1.21 | – | – | $-1.53 |
| Weighted shares, basic | 106.2M | 87.8M | – | – | 67.0M |
| Weighted shares, diluted | 106.2M | 87.8M | 71.1M | 68.9M | 67.0M |
| Margins and growth | |||||
| Operating margin | -327.2% | – | – | – | – |
| Net margin | -339.1% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 16, 2023 | – | – | Jan 29, 2020 |
| Cash and equivalents | $206.5M | $20.3M | $125.8M | $28.2M | $24.9M |
| Total current assets | $403.8M | $138.1M | $191.1M | $151.6M | $202.9M |
| Property, plant and equipment | $465.0K | $701.0K | $1.18M | $1.76M | $2.41M |
| Total assets | $434.7M | $141.9M | $202.3M | $153.8M | $205.7M |
| Accounts payable | $3.83M | $1.10M | $2.73M | $231.0K | $2.50M |
| Total current liabilities | $36.8M | $15.4M | $18.4M | $9.86M | $17.6M |
| Total liabilities | $142.4M | $105.7M | $69.4M | $11.1M | $19.4M |
| Shareholders' equity | $292.3M | $36.2M | $132.9M | $142.7M | $186.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Mar 16, 2023 | – | – | Jan 29, 2020 |
| Operating cash flow | -$72.5M | -$84.1M | -$69.4M | -$44.7M | -$97.9M |
| Capital expenditures | $445.0K | $148.0K | $87.0K | $21.0K | $315.0K |
| Free cash flow | -$73.0M | -$84.2M | -$69.5M | -$44.7M | -$98.2M |
| Depreciation and amortization | $681.0K | $710.0K | $688.0K | $632.0K | $572.0K |
| Stock-based compensation | $15.2M | $9.52M | $10.0M | $7.13M | $9.56M |
| Investing cash flow | -$86.6M | -$46.0M | $48.6M | $48.0M | -$34.3M |
| Financing cash flow | $345.8M | $24.6M | $118.5M | $92.0K | $108.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 49.0% | – | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jan 31, 2024 | 114.7M | +17.9% | SEC |
| Oct 31, 2023 | 113.4M | +33.9% | SEC |
| Jul 31, 2023 | 98.2M | +15.9% | SEC |
| Apr 30, 2023 | 97.5M | +15.2% | SEC |
| Mar 15, 2023 | 97.3M | +14.9% | SEC |
| Oct 31, 2022 | 84.7M | +22.6% | SEC |
| Jul 31, 2022 | 84.7M | +22.7% | SEC |
| Apr 30, 2022 | 84.7M | +22.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.